CD4 and myeloid sarcoma: By coupling immunosuppressive properties on both CD4+ and CD8+ T cell effector responses and neurorepair actions, HGF appears thus to be a promising candidate for the treatment of inflammatory demyelinating neurodegenerative diseases such as MS.